To include your compound in the COVID-19 Resource Center, submit it here.

BioTime reports additional data for Renevia facial lipoatrophy device

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE